Abstract Ovarian ablation improves survival in premenopausal early breast cancer, but the potential added value by luteinizing hormone-releasing hormone (LHRH) agonists to tamoxifen is still not clear. The purpose of our study is to examine the efficacy of the LHRH agonist goserelin for adjuvant therapy of premenopausal breast cancer, the role of interaction between goserelin and tamoxifen and the impact of estrogen receptor (ER) content. A total of 927 patients were included in the Stockholm part of the Zoladex in Premenopausal Patients (ZIPP) trial. They were randomly allocated in a 2 9 2 factorial study design to goserelin, tamoxifen, the combination of goserelin and tamoxifen or no endocrine therapy for 2 years, with or without chemotherapy. This is formally not a preplanned subset analysis presenting the end point first event. In this Stockholm sub-study, at a median follow-up of 12.3 years, goserelin reduced the risk of first event by 32% (P = 0.005) in the absence of tamoxifen, and tamoxifen reduced the risk by 27% (P = 0.018) in the absence of goserelin. The combined goserelin and tamoxifen treatment reduced the risk by 24% (P = 0.021) compared with no endocrine treatment. In highly ER-positive tumours, there were 29% fewer events among goserelin treated (P = 0.044) and a trend towards greater risk reduction depending on the level of ER content. The greatest risk reduction from goserelin treatment was observed among those not receiving tamoxifen (HR: 0.52, P = 0.007). In conclusion, goserelin as well as tamoxifen reduces the risk of recurrence in endocrine responsive premenopausal breast cancer. Women with strongly ERpositive tumours may benefit more from goserelin treatment. The combination of goserelin and tamoxifen is not superior to either modality alone. With the limitations of a subset trial, these data have to be interpreted cautiously.
Introduction
The potential added value by luteinizing hormone-releasing hormone (LHRH) agonists to tamoxifen in the adjuvant setting for premenopausal breast cancer remains unclear. In addition, the optimal timing and duration of LHRH agonist treatment are yet to be defined [1] [2] [3] [4] . Nevertheless, it is clear that ovarian ablation improves survival in premenopausal women with early breast cancer [3] . Results from trials using LHRH agonists in the adjuvant setting have indicated significant benefit in terms of prolonged diseasefree survival and improved survival with 2 years of treatment, regardless of other systemic treatment. Treatment-induced ovarian ablation, whether by endocrine-or chemotherapy, radiation or surgery, results in increased disease-free survival and overall survival in premenopausal endocrine responsive breast cancer [4] . Remaining research questions include the benefit of LHRH agonists, in addition to tamoxifen, and if LHRH agonists have a role among those not achieving amenorrhea during cytotoxic chemotherapy. Moreover, efficacy of endocrine treament in relation to estrogen receptor (ER) status is mainly established among postmenopausal women, and the different endocrine milieu in premenopausal women may affect the predictive ability of ER status [5] [6] [7] [8] .
Overview data on the use of LHRH agonists have not shown therapeutic benefit with combination endocrine therapy versus tamoxifen or goserelin alone in women treated with chemotherapy [3] . The ZIPP trial was included in the overview, and it is the largest one assessing the integration of LHRH agonists into hormonal therapy.
Results from the ZIPP trial have been reported and are recently updated [9, 10] . At a median follow-up of 12 years, 2-years treatment with goserelin was as effective as 2 years of tamoxifen. In those not treated with tamoxifen, there was a large survival and recurrence benefit with goserelin (13.9% fewer events, 95% confidence interval (CI), -19.4 to -7.5), and the addition of tamoxifen to goserelin showed marginal but not statistically significant improvement (2.8% fewer events, CI -7.7-2.0) [10] . One of the limitations of the ZIPP trial is that randomisation was not strict factorial at all participating study sites. Some centres gave tamoxifen electively and only randomised to goserelin or no goserelin. A recent Cochrane review pointed out that results from the trial have not been reported separately for patients who underwent randomisation to both an LHRH agonist and tamoxifen [11] .
As the research question of the benefit of tamoxifen in addition to an LHRH agonist remains unsettled, it was considered reasonable to analyse the Stockholm part of the ZIPP trial separately and examine if the indirect comparisons of the overall trial can be reproduced in the Stockholm cohort. The Stockholm study was initially planned as a separate trial, but as it was found to be underpowered as a stand-alone trial for survival analysis, collaboration with centres in Sweden, UK and Italy (ZIPP trial) was established. This late and formally not planned separate analysis of the Stockholm cohort presents, therefore, only the end point event-free survival (EFS). The Stockholm part of the trial is a strict randomised 2 9 2 factorial subset of the ZIPP trial. In other centres, the analysis made in comparison to the control group is indirect concerning the tamoxifen treatment, because the drug was prescribed electively. In addition, the Stockholm cohort is the only one with complete information on nodal status and whether chemotherapy was given or not. Furthermore, ER status of the primary tumour was available in a high proportion of all randomised women and all assays performed at a single laboratory.
Patients and methods
The ZIPP trial was a collaboration between four research groups (Stockholm, South East Sweden, Cancer Research UK and UCL Cancer Trials Centre (CRC), United Kingdom and Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO), Italy). The study was designed to determine whether the addition of goserelin and/or tamoxifen to adjuvant therapy provided benefit for premenopausal women with early breast cancer as has been described elsewhere [9] .
In Stockholm, all patients were included in a 2 9 2 factorial randomisation to goserelin (3.6 mg sucutaneously every 28 days), tamoxifen (40 mg daily), combination of goserelin and tamoxifen or no endocrine therapy for 2 years. Node-positive women were allocated to adjuvant CMF chemotherapy (six cycles of cyclofosfamide 600 mg/m 2 , methotrexate 40 mg/m 2 and fluorouracil 600 mg/m 2 intravenously administered days 1 and 8, every 28 days), in addition to endocrine therapy. Patients with four or more positive lymph nodes received additional loco-regional radiotherapy, including the chest wall, axillary-and supraclavicular lymph nodes, 46 Gy through 4.5 weeks. Endocrine treatment was given concurrently with chemotherapy.
The randomisation was stratified in three groups based on nodal status and use of other adjuvant therapies: nodenegative patients who received no adjuvant chemotherapy, patients with one to three positive lymph nodes who received chemotherapy and patients with four or more positive lymph nodes who received both chemotherapy and loco-regional radiotherapy (Fig. 1) . Randomisation was carried out by telephone to a central office where the patient identifiers were recorded before the allocated treatment was revealed to the responsible physician. Treatment allocation was based on balanced lists using the permuted block technique.
The inclusion criteria were invasive breast cancer C10 mm, premenopausal menstrual status (defined as last menstruation \6 months earlier), primary surgery consisting of a mastectomy or a wedge resection plus axillary node dissection and no clinical evidence of distant metastases. The exclusion criteria were inoperable breast cancer, previous radiotherapy or neo-adjuvant chemotherapy and previous or concurrent endocrine therapy.
All hormone receptor analyses on tumour samples were performed at a single laboratory, which participated in repeated control studies for receptor determination, using the same technique. The ER content was determined by isoelectric focusing on polyacrylamide gel which has been described elsewhere [12] . The receptor values were normalised to DNA content as measured by Burton and expressed as the binding capacity of estradiol in femtomoles (fmol) per microgram (lg) of DNA [13] . Tumours with a receptor content equal or more than 0.05 fmol/lg DNA were classified as ER-positive, whereas tumours with estrogen content less than 0.05 fmol/lg DNA were classified as ER-negative [6] . The ER-positive tumours were further subdivided into intermediate ER: 0.05-0.59 fmol/lg DNA and high-ER: C0.60 fmol/lg DNA. The study was designed and conducted according to ICH-Good Clinical Practice guidelines and was approved by the Karolinska Institute Regional Ethics Committee.
Statistical methods
Time to event was calculated as time from date of randomisation to date of disease recurrence, contralateral breast cancer, other cancer or death without a reported recurrence, whichever came first. Time for alive and eventfree patients was calculated from the date of randomisation to the common end-date for follow-up, December 31, 2005. Kaplan-Meier technique was used to estimate failure probability, and the log rank test was used to test for difference in time to event between treatment groups. Hazard rate ratios and 95% confidence intervals were estimated using proportional hazards regression. When assessing the main treatment effect of tamoxifen or goserelin, the other treatment was used as control. Test for interactions was performed by inclusion of product terms in the regression models. The analyses were on the basis of intention to treat. No analyses were done on the basis of treatment received. We also analysed the effect of treatment on time to first recurrence according to level of ER content, i.e., ER-negative (\0.05 fmol/lg DNA), intermediate ER (0.05-0.59 fmol/lg DNA) and high-ER (C0.60 fmol/lg DNA). The cutoff for the two ER-positive groups was made at a level, which created equally sized groups. Data on ER content were available on 793 patients (86%). Interaction between treatments and ER content were further investigated graphically by use of Subpopulation Treatment Effect Pattern Plots (STEPP) [14] . The STEPP analysis was performed using the program stepp_tail, implemented in the statistical software Stata [15] .
Results
A total of 927 women in Stockholm were recruited to the study from May 31, 1990, to January 8, 1997. Of the 927 recruited women, 234 were randomised to the control (C) arm, 231 were randomised to receive goserelin (G), 231 to tamoxifen (T) and 231 to goserelin plus tamoxifen (GT) therapy. Patient characteristics were well balanced between the treatment groups as seen in Table 1 . Nodal status was known for all women and hormone receptor status reported for 86% of the women included in the analysis. One woman was incorrectly randomised twice and one woman was diagnosed with recurrent disease at the date of randomisation. The remaining 925 women were included in the analysis.
The common end of follow-up was January 1, 2006. After a median follow up time of 12.3 years, 166 women presented with loco-regional recurrence as a first event, 159 had distant metastases, 54 had contra-lateral breast cancer, 50 women were diagnosed with other cancers and there were 6 deaths as first event. The overall number of deaths from breast cancer was 225 and there were 26 non-breast cancer deaths. The total number of first events was 435. There were 128 (55%) first events in the C group, 98 (42%) in G treated, 101 (44%) among T treated and 108 (47%) in the GT group.
Three main sets of analyses were carried out: First the overall effect of endocrine therapy versus no endocrine therapy, second, the effect of goserelin with or without tamoxifen and finally, the effect of tamoxifen with or without goserelin.
In the first set of analysis, the control group was used as a reference. In comparison to the controls, endocrine treatment with either goserelin alone, combined with tamoxifen or tamoxifen alone reduced the risk of first recurrence by 32% (CI, 0.52-0.89), 24% (CI, 0.59-0.98) and 27% (CI, 0.56-0.94), respectively (P = 0.021) (Fig. 2) . The second analysis showed that goserelin treatment reduced the risk of first recurrence by 16% (CI, 0.68-1.02). There was no additional beneficial effect of goserelin with tamoxifen, but in the absence of tamoxifen, first recurrence was reduced by 32% (CI, 0.53-0.89). In the third set of analysis, we examined the effect of tamoxifen. The main effect of tamoxifen was not statistically significant (HR: 0.89, CI, 0.74-1.08), but when examined separately for those not treated with goserelin, there was a 27% benefit for tamoxifen (CI, 0.56-0.95). A test for interaction between goserelin and tamoxifen was statistically significant (P = 0.025) (Table 2, Fig. 3 ).
When we examined the treatment effect for different levels of ER content, there was an overall effect of goserelin in the high-ER group (HR: 0.71, CI, 0.50-0.99, P = 0.044) and a trend towards greater risk reduction with increasing levels of ER content (Fig. 4) . The greatest risk reduction from goserelin treatment in the group with high ER was observed among those not receiving tamoxifen (HR: 0.52, CI, 0.32-0.84, P = 0.007).
The main effect of tamoxifen in the high-ER group was not significant (HR: 0.85, CI, 0.61-1.18) (Fig. 4) (Fig. 4) .
Discussion
In previously published and recently updated ZIPP trial analysis, some inconsistencies in the study design were noted, i.e., randomisation to tamoxifen had been optional in some centres [9, 10] . Subsequently, some women received tamoxifen electively. The Stockholm and GIVIO centres alone maintained the 2 9 2 factorial randomisation throughout the trial. In addition, the Stockholm cohort was well defined according to hormone receptor content, nodal status and whether chemotherapy and/or radiotherapy was given or not.
The ZIPP trial was included in the meta-analysis of the Early Breast Cancer Overview group, which concluded that LHRH agonists alone are effective in the adjuvant setting in hormone receptor positive breast cancer, both in terms of recurrence-free and overall survival. The optimal timing and duration of use, however, remains unclear and there is lack of data from randomised trials where LHRH agonists are tested against chemotherapy, with or without tamoxifen in both arms [3] . Our results from the present Stockholm sub-cohort are in concordance with the previously published results of the conjoint ZIPP trial data, where goserelin effect on recurrence is considerable and the most marked effect is seen among those not receiving concomitant tamoxifen. The pooled trial results also showed a survival benefit not possible for us to examine here because of a small sample size. Despite the limited sample size, the strength of this report is the strict randomised design and execution of the study, as recently recommended by the Cochrane review group. This design allows a formal test of interaction that is not possible for the overall trial data of 2,706 patients. Furthermore, the single-laboratory analyses of ER content with a quantitative cytosol method allowed an analysis of the effect of different receptor levels on outcome. This formal test of interaction between goserelin and tamoxifen in a randomised cohort confirms the indication made in the Hackshaw report that tamoxifen provides no additional benefit among women treated with goserelin [10] . The same is true for the opposite, where goserelin provides no additional benefit for tamoxifen treated. Tamoxifen is effective in extending the time to first recurrence, but only among those not receiving goserelin. The lack of additional benefit of combined endocrine therapy has previously been demonstrated in the postmenopausal adjuvant as well as the metastatic setting [16, 17] . As our study is not powered for survival analysis, the ongoing Suppression of Ovarian Function Trial (SOFT) should answer the question of the effect of combination endocrine therapy in the premenopausal setting, more decisively. In our strictly randomised cohort, the analysis of estrogen receptor levels confirms the lack of effect on ER-negative women, in line with previous reports [18] . An intriguing finding is, however, that the effect of goserelin increases with higher ER levels, whereas the same does not apply for tamoxifen. This may be a finding of chance, but the data indicate a clear difference, which may be based on biological grounds. Goserelin, which has stronger estrogen suppressor effect compared with tamoxifen, is potentially more effective when ER content is high. In this group, tamoxifen may not have sufficient effect to counteract the highly estrogenic milieu of premenopausal women. The STEPP plots demonstrating this effect are, however, based on small subsets of patients, and the data therefore have to be interpreted conservatively. Among postmenopausal women, earlier studies have shown a significant trend in reduction of recurrence rate with higher ER levels among tamoxifen treated, supporting the significance of stronger ER content in endocrine treatment [5] [6] [7] [8] .
Quality of life aspects and the long-term side effects are important factors to be taken into consideration when assessing improvements in adjuvant therapy. The overview has shown that goserelin is an option for women where chemotherapy is contraindicated or strongly opposed to cytotoxic drugs [3] . Premature menopause is highly probable after chemotherapy and desire for pregnancy is not uncommon after completed treatment. Moreover, some women may be reluctant to the adverse effects of permanent ovarian failure, such as infertility and accelerated bone loss. These factors have been studied extensively in the Stockholm cohort and reported in several publications [19] [20] [21] [22] . Our study on ovarian function showed that amenorrhea among goserelin and chemotherapy treated was more often reversible compared with those not receiving goserelin [19] . We did not observe this effect among women who received tamoxifen in addition to goserelin. However, there was lack of power for analysis of survival effect from different endocrine treatment in the subset of women that developed chemotherapy induced amenorrhea. Results from studies examining the possible protective effect of goserelin on ovarian function are nevertheless conflicting and results from ongoing trials are awaited. Our study on bone mineral density (BMD) showed a substantial but reversible decrease in BMD after 2 years of goserelin therapy, whereas the addition of tamoxifen to goserelin resulted in less changes in BMD [20] . The possible role of aromatase inhibitor (AI) treatment in combination with LHRH agonist is not clear but the addition of AIs is likely to exaggerate the bone effects further. At present, there are limited data on this approach in the adjuvant setting, but AI's have shown a marked effect on bone metabolism. The Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial showed that zoledronic acid not only counteracts effectively the demineralising effects from goserelin but also improves disease-free survival as well [2] . Accordingly, bone loss is manageable and should not restrict the use of goserelin. Further studies on the Stockholm cohort showed that sexual dysfunction as well as physical effects from goserelin diminished with time, whereas chemotherapy-related symptoms were ongoing at follow-up at 3 years [21, 22] .
A limitation of the Stockholm study may be the 2 years of 40 mg/day tamoxifen, which was standard at the time, instead of 5 years of 20 mg/day treatment as currently recommended. In contrast to tamoxifen, 2 years of goserelin is still within the recommended treatment period, although the optimal duration of treatment is not yet determined. Another limitation is the concurrent use of chemotherapy in the trial, which may not be optimal based on the risk of endocrine therapy interaction with chemotherapy, and sequential treatment currently being recommended as a standard. However, this concern is primarily based on the report by Albain et al. and the study lacked power to reveal significant statistical difference, although the hazard ratio indicates that concurrent therapy should not be given [23] .
In conclusion, goserelin is effective in reducing risk of recurrence and improving survival in endocrine responsive premenopausal breast cancer. These effects are not enhanced further by the addition of tamoxifen, and there is a significant interaction between goserelin and tamoxifen. Quality of life is affected and side effects are considerable from goserelin, but they are manageable and moreover, reversible. This study indicates that there may be an additional subgroup of women besides the very young, i.e., those with strongly ER-positive tumours, who benefit more from goserelin treatment, whereas the effect of tamoxifen does not seem to be modified by ER content. A significant interaction indicates that the effect of goserelin depends on whether tamoxifen is given or not and the effect of tamoxifen depends on whether goserelin is given or not. Our data support that there is no additional benefit from combination endocrine therapy in the premenopausal setting. Within the limitations of the exploratory approach and limited power as a stand-alone trial, our results should be viewed mainly as hypothesis generating awaiting data from ongoing trials such as SOFT.
